Received SEC

OCT 03 2017

Washington, DC 20549

William Slattery, CFA Vice President Listing Qualifications



Electronic Mail Only

October 3rd, 2017

Mr. Jeffrey Thomas Chief, IT Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549



17010896

Dear Mr. Thomas:

This is to certify that on October 3rd, 2017 The Nasdaq Stock Market (the "Exchange") received from Rhythm Pharmaceuticals, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Common stock, par value \$0.001 per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Lattery